eligibility_summary
Eligible: cHL confirmed, PD-(L)1-refractory, no remaining effective therapies, adequate marrow and organ function. Exclude: CNS metastases/involvement, systemic anticancer therapy within 4 weeks, prior anti-CD47 or SIRPa therapy, HIV, active autoimmune disease needing systemic treatment in past 2 years (except replacement), severe allergy to study drug components, humanized antibodies, or fusion proteins.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase III, open-label trial in PD-(L)1–refractory classical Hodgkin lymphoma. Experimental arm: IMM01 (Timdarpacept) + tislelizumab. IMM01 is a recombinant SIRPα–Fc fusion protein (biologic) that binds CD47 on tumor cells, blocking the CD47–SIRPα “don’t-eat-me” signal to promote macrophage-mediated phagocytosis and antigen presentation (targets macrophages/dendritic cells, CD47–SIRPα innate checkpoint). Tislelizumab is a humanized IgG4 monoclonal antibody (immune checkpoint inhibitor) against PD‑1 that blocks PD‑1/PD‑L1 to reinvigorate T cells (targets T cells, PD‑1 pathway). Comparator: physician’s choice chemotherapy—bendamustine (alkylating agent causing DNA crosslinks) or gemcitabine (nucleoside analog inhibiting DNA synthesis)—cytotoxic to proliferating lymphoma cells.